據報內地考慮重啟螞蟻集團IPO 阿里美股盤前股價轉升3.6%
《彭博通訊社》報道,螞蟻集團早前中斷的中港兩地上市計劃,據稱被監管部門重新提上議事日程,有望成為科技行業目前為止最具標誌性的政策轉捩點信號。
報道引述知情人士指,中國證監會已經設立一個工作小組,評估重啟螞蟻集團A股上市的可行性方案。而監管機構對螞蟻集團金融控股公司牌照的申請,已接近批准前的最後階段。
另一位知情人士指,螞蟻集團仍期望最終在上海和香港兩地上市。公司最新聘請港交所董事會主席史美倫擔任獨立董事的舉動,反映得到監管部門的認可,亦顯示其上市事宜取得進展。其中一位知情人士指,監管部門最近幾周對螞蟻集團的重組提議加快了決策進程。
阿里巴巴美股盤前由跌轉升,最新升3.6%,報124.2美元,較港股收市價高9.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.